Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Add as a preferred source on Google
EDEN PRAIRIE, Minn., April 02, 2018 -- CHF Solutions (Nasdaq:CHFS), today announces that it will present at The MicroCap Conference on April 9, 2018.
The company’s CEO, John Erb, will present at 2:00 PM ET at The Essex House in New York City. The company will also be available for one-on-one investor meetings. Interested investors may request a meeting time by contacting Bret Shapiro, COREIR, either by calling 516-222-2560 or via [email protected].
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
[email protected]
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
[email protected]
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
[email protected]
